AJ 502
Alternative Names: AJ-502Latest Information Update: 24 Feb 2021
At a glance
- Originator AnnJi Pharmaceutical
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 31 Dec 2020 Preclinical trials in Psoriasis in Taiwan (Topical, Cream) before December 2020 (AnnJi Pharmaceutical pipeline)
- 31 Dec 2020 Preclinical trials in Psoriasis in Taiwan (Topical, Ointment) before December 2020 (AnnJi Pharmaceutical pipeline)
- 31 Dec 2020 Pharmacodynamics data from a preclinical trials in psoriasis released by AnnJi Pharmaceutical before December 2020 (AnnJi Pharmaceutical website)